Mereo Biopharma Group Plc (MAH0) AI Stock Analysis

1 Followers

Mereo Biopharma Group Plc

(Frankfurt:MAH0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverageVery low leverage reduces near-term solvency pressure and leaves the company less exposed to interest costs or refinancing demands. This provides some financial flexibility while Mereo advances its clinical pipeline and seeks partnership-related funding.

Negative Factors

Persistent cash burnMereo remains dependent on external funding, partnerships, or future milestone receipts because operations are not self-financing. Continued negative cash flow can shorten liquidity duration and constrain investment in clinical programs if expected inflows are delayed.

Mereo Biopharma Group Plc (MAH0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 48.96M
Dividend Yield: ―
Average Volume (3M): 3,266
Price to Earnings (P/E): -1.7
Beta (1Y): 0.02
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 39
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Mereo Biopharma Group Plc Business Overview & Revenue Model

Company Description

Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the c...

Mereo Biopharma Group Plc Risk Analysis

Mereo Biopharma Group Plc disclosed 73 risk factors in its most recent earnings report. Mereo Biopharma Group Plc reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Mereo Biopharma Group Plc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:MAH0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GANX	48Neutral	$47.14M	-2.64	-133.17%	―	―	33.17%
MIST	44Neutral	$82.44M	-0.96	-288.36%	―	―	21.42%
CRVO	42Neutral	$20.73M	-0.64	-164.95%	―	-99.86%	4.48%
ANVS	41Neutral	$37.31M	-0.48	-685.96%	―	―	11.96%

* Healthcare Sector Average

Performance Comparison

DE:MAH0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:MAH0	Mereo Biopharma	0.26	-1.26	-83.10%
CRVO	Cervomed Inc.	1.77	-5.48	-75.59%
MIST	Milestone Pharmaceuticals	0.66	-1.24	-65.16%
ANVS	Annovis Bio Inc	0.85	-1.44	-62.75%
GANX	Gain Therapeutics, Inc.	1.11	-1.88	-62.88%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Mereo Biopharma Group Plc AI Stock Analysis